Modeling human tumor evolution in mice
Cancer develops through an evolutionary process driven by mutation and selective pressures imposed by the microenvironment. To be translationally relevant, experimental models must recapitulate these clinical complexities. In this Primer, we consider how different mouse-modeling strategies can be aligned with human tumor evolution, focusing on mutation order, the emergence and competition of initially rare mutant clones within genetically mosaic tissues, and microenvironmental context. By comparing conventional genetically engineered mouse models (GEMMs), transplant-based models, and emerging tools such as somatic editing and the tandem arrayed regulator (TAR) allele system, we offer a guide for selecting the most appropriate mouse model to address specific evolutionary questions.
Authors
- Dale M. Watt (ORCID: https://orcid.org/0000-0002-0443-176X)
- Daniel J. Murphy (ORCID: https://orcid.org/0000-0002-5538-5468)
- S. Leah Etheridge
- Karen Blyth (ORCID: https://orcid.org/0000-0002-9304-439X)
- Louise E. Mitchell (ORCID: https://orcid.org/0009-0004-3173-5074)
- Philip D.; id_orcid 0000-0001-9160-283X Dunne
Institutions
- Queen's University Belfast (GB)
- Cancer Research UK Scotland Institute (GB)
- University of York (GB)
- University of Glasgow (GB)
Publication Details
- Journal
- STAR Protocols
- Published
- 2026-10-03
- DOI
- https://doi.org/10.1016/j.xpro.2026.104872
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00